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CONTINUING EDUCATION
A Pharmacist’s Role in the Prevention and Management of 
Perioperative Atrial Fibrillation and Flutter
CONTINUING EDUCATION II
by Amanda Harmon, Pharm.D. Candidate Class of 2015; Bethany Smith, Pharm.D. Candidate Class of 2015; 
Laura Tsu, Pharm.D., BCPS; Midwestern University College of Pharmacy – Glendale
Goal:
This home-study CPE has been developed to educate 
pharmacists about recently published guidelines for 
perioperative atrial fibrillation and flutter management 
and prevention, and discuss the role a pharmacist can 
have in the care of these patients.
At the conclusion of this lesson, successful participants 
should be able to:
Objectives for Pharmacists: 
1. Summarize the complications of post-operative atrial 
fibrillation (POAF)
2. Define POAF in terms of electrocardiogram (EKG) findings 
and clinical signs and symptoms
3. List rate control agents and their mechanism of action 
and monitoring parameters
4. List rhythm control agents and their limitations
5. Identify potential candidates for rhythm control of POAF 
6. Justify the preventative strategies recommended by the 
POAF guidelines
7. Formulate an appropriate treatment plan for new-onset 
POAF
8. Discuss management of anticoagulation for patients with 
preexisting atrial fibrillation
Objectives for Technicians: 
1. Understand some of the complications of post operative 
Atrial Fibrillation 
2. List rate control agents and what they are used for 
3. List rhythm control agends and what they are used for
4. Learn preventative strategies recommended by POAF 
guidelines
Introduction
       Although thoracic surgeries save the lives of thou-
sands of people every year, they are also associated 
with an increased risk of cardiac arrhythmias, such as 
atrial fibrillation (Afib). High risk procedures, such as 
lung transplantations and esophagectomies have been 
found to have greater than a 15% incidence of Afib 
following surgery.1 Atrial fibrillation/flutter is the most 
common sustained arrhythmia associated with thoracic 
surgery.1 This adverse outcome is potentially prevent-
able, and pharmacological therapy can play key role in 
the care plan of these patients. 
       Afib is an irregular heart rhythm caused by chaotic 
contracting of the atria of the heart. This lack of syn-
chronized beating can result in poor perfusion of 
the body due to insufficient blood flow and in-
creases the risk of emboli formation due to venous 
stasis. Common clinical signs and symptoms of Afib 
may include hypotension, dizziness, decreased 
urinary output, and fatigue.1 On an electrocardio-
gram (EKG), Afib is characterized by no discernible 
P waves and an irregularly irregular rhythm. 
       Postoperative/perioperative atrial fibrillation/
flutter (POAF) is Afib that occurs specifically during 
the postoperative period and can be due to sever-
al factors. The risk factors for the development of 
POAF are the same as those for the development 
of Afib in nonsurgical patients.1 Oftentimes, the 
stress of the surgery alone can be a risk factor for 
experiencing an arrhythmia.1 The onset of POAF 
most commonly occurs between two and four 
days following surgery, and up to 98% of cases 
resolve after six weeks.1 This adverse outcome is 
a concern, however, because it can lead to hemo-
dynamic instability, thrombus formation and even 
heart failure due to sustained tachycardia. Risk of 
POAF varies with the intensity of the cardiothoracic 
surgery, higher risk coinciding with more invasive 
and intense procedures. Other risk factors include 
older age, hypertension, obesity, and smoking.1 
See Table 1 for a more complete list of modifiable 
and non-modifiable risk factors. The most serious 
adverse event of POAF is formation of thrombo-
emboli, which can lead to stroke and/or acute limb 
ischemia. 
       Post-operative Afib is associated with an in-
creased length of stay in the hospital, increased 
morbidity and mortality, and increased healthcare 
costs.1 Some studies have shown POAF to result 
in increased length of stay by an average of three 
days, and increased costs of care by up to 30%.2 It 
is important for the pharmacist to be informed of 
the current best practices in the management and 
prevention of POAF to lead to better treatment 
outcomes in this patient population.
Guidelines
       Previously, management and prevention of 
POAF has been directed by the Society of Thoracic 
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Surgeons (STS) guidelines published in in the Journal 
of Thoracic and Cardiovascular Surgery in 2011.3  In 
September of 2014 the American Association for Tho-
racic Surgery (AATS) published guidelines for POAF, 
titled “2014 AATS guidelines for the prevention and 
management of perioperative atrial fibrillation and 
flutter for thoracic surgical procedures” in the Journal 
of Thoracic and Cardiovascular Surgery.1 These guide-
lines discuss new information and advances in POAF 
therapy and provide updated recommendations on 
the management of this condition. 
The clinical guidelines start by providing definitions 
for POAF as both an electro-physiologic and clinical 
diagnosis. They recommend that the diagnosis of 
POAF include clinically significant POAF that requires 
treatment in addition to an EKG reading of Afib 
lasting longer than 30 seconds.1 Patients at risk for ar-
rhythmias or those who have substantial risk factors 
for stroke should be continuously monitored via EKG 
telemetry during the postoperative period to detect 
any changes in rhythm. 
       The guidelines go on to recommend and review 
various strategies for preventing POAF. Next, for 
patients in whom new-onset POAF occurs, potential 
treatment options are identified. The specifics of 
these recommendations are discussed in the follow-
ing sections and are the bulk of these clinical guide-
lines. Finally, recommendations for patients with pre-
existing Afib are provided, particularly with regards to 
anticoagulation management. 
Prevention of Postoperative Atrial Fibrillation
       Postoperative Afib is a potentially serious compli-
cation of thoracic surgery and can be a preventable 
incident. Recent evidence indicates that prevention 
strategies previously reserved for high risk patients 
may in fact be effective in all thoracic surgical pa-
tients. The strongest preventative recommendation 
provided by the 2014 AATS guidelines is that all 
patients taking β-blockers before surgery should con-
tinue them in the postoperative period (class I rec-
ommendation, indicating that the benefit outweighs 
the risk).1 This recommendation is resultant of several 
large meta-analyses and randomized studies, mostly 
from cardiac surgery literature, that have shown with-
drawal of β-blockers prior to surgery increases the 
risk of developing POAF.1 It is thought that elevated 
levels of norepinephrine in patients taking β-blockers 
preoperatively with an interruption in therapy is asso-
ciated with this higher risk.4 This recommendation is 
in agreement with the 2011 ACCF/AHA Guideline for 
Coronary Artery Bypass Graft (CABG) Surgery which 
also suggest that beta-blockers be used both pre and 
post-operatively.5 A second POAF prevention recom-
mendation for all thoracic surgery patients, level class 
IIb (benefit ≥ risk), is to replenish serum magnesium 
stores when levels are depleted with intravenous 
magnesium supplementation.1 Finally, the guidelines 
classify the use of digoxin as a class III recommenda-
tion, advising against its use for preventing POAF.1 
This is based off of current literature showing that 
digoxin has been ineffective in preventing periop-
erative Afib.6  This is supported by the Guidelines 
for CABG Surgery, which state that both digoxin and 
nondihydropyridine calcium channel blockers (non-
DHP CCBs) are not indicated for prophylaxis of POAF.5    
It is important for the pharmacist to recognize these 
pharmacological recommendations made by AATS so 
that they can ensure the presence of evidence-based 
therapy in preoperative patients to minimize risk. 
       For patients with an intermediate to high risk for 
POAF additional strategies are offered. The guidelines 
suggest that diltiazem can be considered as a prophy-
lactic agent in patients who are not taking β-blockers 
preoperatively, as a class IIa recommendation (benefit 
outweighs the risk).1 Diltiazem generally does not 
have the same blood pressure lowering effects that 
β-blockers can have, and may be a good alternative 
for patients in whom postoperative hypotension is 
a concern. Its ability to decrease the risk of POAF is 
thought to be related to its ability to decrease pul-
monary vascular resistance.7 Other pharmacological 
interventions discussed in the guidelines for these 
higher risk patients include the use of intravenous 
amiodarone postoperatively and initiation of ator-
vastatin in statin-naïve patients for the prevention 
of POAF.1 The practice of using amiodarone postop-
eratively as prophylaxis is frequently seen in cardio-
vascular surgeries. This is largely due to the recom-
mendations provided by the Guidelines for CABG 
Surgery, which also suggest that amiodarone can be 
used to decrease the risk of POAF.2 AATS specifically 
recommends this practice for pulmonary resection 
and esophagectomy procedures in this publication. 
The recommendation for initiation of atorvastatin 
is derived from the analysis of several studies in-
vestigating this indication. It is thought that statins 
down-regulate the renin angiotensin system, and that 
it is through this mechanism that this class reduces risk 
of Afib.8 Other novel prophylactic strategies continue 
to be studied for additional options of POAF prevention 
in these patients. 
Management Strategies for New-onset POAF
       For patients in whom POAF occurs, possible trig-
gering causes should be carefully considered. Although 
the irritation from the thoracic surgery itself is often 
enough to explain new-onset POAF, other factors 
should be considered so that they can be reduced or 
removed if present. Examples of this include bleeding, 
pulmonary embolism, airway compromise, and infec-
tion. In addition the guidelines recommend that cate-
cholaminergic inotropic agents, such as dobutamine, 
be reduced or stopped when hemodynamics allow. 
Careful management of fluids and electrolytes is also 
advised in patients with new-onset POAF, as an imbal-
ance in these can be a trigger. These strategies are all 
class I recommendations found in the 2014 guidelines, 
again indicating that the benefit outweighs the risk.1
Once possible triggers of Afib are assessed and re-
moved where possible, treatment of the arrhythmia 
should be addressed. There are two approaches that 
can be considered for the treatment of Afib: rate 
control or rhythm control. The 2014 AATS guidelines 
recommend that rate control therapy be used first-line 
for stable patients with POAF.1 This recommendation 
is based largely off of a landmark study named the 
AFFRIM trial that was published in 2002 in the New 
England Journal of Medicine. This study showed that 
rate control was as effective as rhythm control for the 
primary endpoints of death and incidence of ischemic 
stroke, with fewer adverse drug events (ADEs) occur-
ring in the rate control group.9 It is important to note, 
however, that regardless of which treatment method is 
used anticoagulation for patients who have been hav-
ing episodes of Afib lasting longer than 48 hours should 
be strongly considered. The guidelines recommend 
using the CHA2DS2-VASc scoring system to determine 
stroke risk in these patients. This scoring system is 
shown in Figure 1. Pharmacists should be aware of the 
different treatment options and their clinical pearls, 
since many of the medications used in these approach-
es have several side effects and monitoring parame-
ters. The following sections discuss the two treatment 
approaches, emphasizing the medications that fall 
under each category. 
Rate Control Recommendations
       The 2014 AATS POAF guidelines recommend 
that rate control therapy be initiated as the first-
line treatment option in hemodynamically stable 
patients in whom POAF occurs. The following 
agents are endorsed by the guidelines as being 
effective for rate control. Rate control in POAF can 
be achieved using intravenous (IV) or oral agents. 
IV β-blockers and non-DHP CCBs, such as diltiazem 
and verapamil, are commonly used since they can 
often achieve rate control faster than other agents. 
This section discusses the mechanisms of action of 
the agents, as well as common side effects, dosing 
recommendations, and contraindications/limita-
tions. Important monitoring parameters for these 
medications include EKG telemetry monitoring, 
vital signs including blood pressure and heart rate, 
electrolytes, and other labs such as serum creati-
nine (SCr) and complete blood count (CBC). A sum-
mary of these medications can be found in Table 2.
β-blockers:
      β-blockers are Vaughan Williams class II agents. 
Classification of the Vaughn Williams agents is 
shown in Figure 2. These agents block the response 
to β-adrenergic stimulation thereby decreasing 
heart rate. Metoprolol is a commonly used β-block-
er in Afib that is β-1 selective and as a result mainly 
affects only cardiac tissue. IV dosing of metoprolol 
tartrate (Lopressor) is 2.5-5.0 mg IV bolus over 
2 min for a maximum of three doses.10 Esmolol 
(Brevibloc) is a nonselective β-blocker with a quick 
onset and shorter duration of action compared to 
metoprolol. Esmolol is dosed intravenously at 0.5 
mg/kg IV bolus over 1 min, then 0.05-0.3 mg/kg/
min IV continuous infusion.11 Both medications 
reduce ventricular response in patients with Afib 
within 5 minutes of administration. Significant 
limitations and known side effects of β-blockers 
include bradycardia, hypotension, bronchospasm 
due to β-2 blocking activity, and avoidance of use 
during heart failure exacerbation. Patients with 
systolic heart failure and/or CAD have a compelling 
indication for β-blocker therapy including the use of 
carvedilol, metoprolol succinate, and bisoprolol as 
these have favorable mortality data.
Non-DHP CCBs:
Diltiazem (Cardizem) is a non-DHP CCB and class IV 
Vaughan Williams agent. IV diltiazem administered 
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as a bolus and continuous infusion can control ventric-
ular response in 70-90% of patients with recent-onset 
Afib. The onset of action of diltiazem is 2-7 min. The 
Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial found oral diltiazem effica-
cious in controlling rest and exercise heart rate in ap-
proximately 60% of patients.9 Recommended IV dosing 
of diltiazem is 0.25 mg/kg IV loading dose over 2 min, 
then 5-15 mg/hour IV continuous infusion.12 A second 
non-DHP CCB used for rate control is verapamil (Calan). 
The recommended IV dosing for verapamil is 0.075 to 
0.15 mg/kg (~ 5 to 10 mg for a 70-kg patient) adminis-
tered as a bolus over 2 minutes; may give an additional 
10 mg after 30 minutes if no response, then 0.005 mg/
kg/minute as a continuous infusion.13 Common side 
effects of the non-DHP CCBs include hypotension, 
bradycardia, and constipation. Limitations of non-DHP 
CCBs include use during heart failure exacerbations as 
this class of medication can worsen heart failure. 
Digoxin (Lanoxin):
       Digoxin’s mechanism of action is inhibition of sodi-
um potassium ATPase. This enzyme, commonly known 
as the sodium-potassium pump, is responsible for 
transporting sodium ions out and potassium ions into 
cells. Inhibition of this pump causes increased intracel-
lular sodium concentrations which leads to increased 
intracellular calcium concentrations. Digoxin increases 
the force and velocity of myocardial systolic contraction 
but also slows heart rate. Digoxin has positive inotropic 
and negative chronotropic effects. This is significant 
since it does not cause hypotension which is a limita-
tion to many of the other Afib medications. The loading 
dose for IV digoxin is 0.5 to 0.75 mg bolus followed by 
0.25 mg IV every 2-6 hours to a maximum dose of 1.5 
mg over 24 hours. This dosing has an onset of action 
of 30 minutes to 2 hours.14 The maintenance dose is 
based on lean body weight, renal function, age, and 
concomitant medications. Digoxin is effective for rate 
control at rest but requires concomitant use with either 
a β-blocker or non-DHP CCB to achieve exercise rate 
control. Therefore, digoxin should only be used as com-
bination therapy rather than monotherapy. Also, digox-
in should not be used for prophylaxis against Afib.   It is 
important to monitor electrolytes in patients taking di-
goxin since digoxin toxicity is potentiated by hypokale-
mia, hypomagnesemia, or hypercalcemia. Symptoms of 
digoxin toxicity include nausea and vomiting with pos-
sible anorexia, dizziness, weakness, mental disturbanc-
es (such as confusion or hallucinations) and blurred 
or yellow vision. In addition, concomitant use of 
digoxin with amiodarone, dronedarone, or ver-
apamil can worsen symptoms of toxicity as these 
medications can increase serum digoxin levels. The 
mechanism of interaction is likely due to inhibi-
tion of P-glycoprotein (P-gp) resulting in increased 
bioavailability of digoxin. Patients that present with 
symptoms of toxicity should have their serum drug 
concentration checked as this medication has a 
narrow therapeutic window. The goal therapeutic 
range of digoxin for the indication of Afib is 0.8 to 
2.0 ng/mL.14 There is no added treatment benefit 
with serum concentrations above 2.0 ng/mL; how-
ever, risk for toxicity increases substantially beyond 
that point. Furthermore, it is possible for patients 
to fall in the therapeutic range but still present with 
symptoms of toxicity. Digoxin serum concentrations 
should be drawn at least 6 hours after the last dose 
if given IV or at least 8 hours after the last dose 
if given orally. Levels should not be drawn within 
2 hours of exercise because of increased skeletal 
muscle uptake of digoxin. Digoxin accumulates in 
acute kidney injury and chronic kidney disease so 
it is justified to check serum drug concentration 
after one week of therapy. Patients with recurrent 
hospitalization for HF exacerbation, hypotension, 
or who are sedentary/bed-bound have compelling 
indications for treatment with digoxin.
Rhythm Control Recommendations
      Rhythm control therapy can be considered in 
patients who have symptomatic POAF but are he-
modynamically stable. Restoration of normal sinus 
rhythm (NSR) through pharmacologic cardioversion 
will generally eliminate symptoms of POAF and 
may lead to better overall patient satisfaction. This 
method of POAF treatment may also be considered 
in patients where rate control agents are ineffective 
or intolerable. This section reviews antiarrhythmic 
agents, their mechanisms of action, potential ADRs, 
dosing recommendations, and contraindications/
limitations. Specific agent choice depends on 
several factors, including presence of underlying 
structural heart disease, renal function, potential 
toxicities, and provider experience. These medica-
tions require careful monitoring to minimize ADRs 
and toxicities, which can lead to additional arrhyth-
mias, extracardiac toxicities, and increased length 
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of hospital stay. Important monitoring parameters for 
these medications include EKG telemetry monitoring 
with QTc interval measurement, vital signs including 
blood pressure and heart rate, electrolytes, and oth-
er labs such as serum creatinine (SCr) and complete 
blood count (CBC). Additionally, signs and symptoms 
of toxicities should be assessed frequently. A summa-
ry of these medications can be found in Table 3.
Amiodarone (Nexterone - IV, Pacerone - Oral):
Amiodarone prolongs the action potential by inhibit-
ing the inward potassium current and is therefore a 
Vaughan Williams class III agent. It is also a noncom-
petitive α- and β-adrenergic inhibitor. Amiodarone 
can be used for cardioversion from Afib to sinus 
rhythm or for maintenance of sinus rhythm. Cardio-
version dosing consists of 150 mg IV over 10 minutes, 
then 1 mg/minute for 6 hours, then 0.5 mg/minute 
for 18 hours or change to oral maintenance dosing 
of 100-400 mg daily.15 The 2014 AATS Guidelines for 
POAF recommend prophylactic amiodarone dosing 
of 300 mg IV bolus, then 600 mg orally twice daily for 
3-5 days. The IV bolus and first oral dose of 600 mg 
are to be given together immediately after surgery. A 
variety of regimens for preventing POAF have been 
used in clinical trials but the AATS guideline recom-
mendation is based on the dosing regimen utilized 
in a randomized, double-blinded, placebo controlled 
trial in patients undergoing surgery for lung can-
cer.16 Amiodarone has an unpredictable time course 
of effect so loading doses should only be adminis-
tered in a hospital setting. Acute adverse effects of 
amiodarone include bradycardia, QT interval prolon-
gation, arrhythmias, and hypotension. Heart rate and 
blood pressure should be monitored regularly. Base-
line QT interval should be measured with additional 
follow up measurements throughout the course of 
treatment along with electrolytes.  More serious 
adverse effects are seen in long-term amiodarone 
use like pulmonary toxicity, hepatic disorders, hyper 
or hypothyroidism, neurologic disorders including 
fatigue and peripheral neuropathy, blue skin discolor-
ation, and visual disturbances. Additional monitoring 
includes baseline chest x-ray, pulmonary function 
tests, liver function test, and thyroid function. These 
should also be monitored periodically during therapy 
along with routine eye exams.  Amiodarone should 
be used cautiously in patients on oral anticoagulation 
as it inhibits the metabolism of warfarin and inhibits 
the elimination of the new oral anticoagulants. There 
is no well-established relationship between plasma 
concentration and effectiveness so serum drug con-
centration monitoring is not warranted. 
Flecainide (Tambocor):
      Flecainide is a Vaughan Williams class IC antiar-
rythmic agent. It slows conduction in cardiac tissue 
by altering transport of ions across cell membranes. 
Flecainide is only manufactured as an oral dosage 
form in the United States. Dosing for conversion to 
sinus rhythm is 200-300 mg as a single oral dose 
and sinus rhythm is maintained by 50-150 mg orally 
every 12 hours.17 Adverse effects include dizziness 
and visual abnormalities such as blurred vision and 
difficulty focusing. Flecainide is less tolerated in pa-
tients with structural heart disease as these patients 
may experience ventricular proarrhythmias. Flecain-
ide is contraindicated in patients with heart failure 
with reduced ejection fraction (HFrEF), due to potent 
negative inotropic activity, and in coronary artery 
disease (CAD)/structural heart disease. Additionally, 
class IC antiarrythymic medications are listed in the 
Beers Criteria so they are not first-line treatment for 
Afib in the geriatric population.18 Select patients are 
eligible for the “pill-in-the-pocket” administration ap-
proach for cardioversion. Eligible candidates for this 
approach have infrequent paroxysmal atrial fibrilla-
tion with no other cardiac symptoms and have no 
structural heart disease. These patients take either 
flecainide or propafenone on an as-needed instead 
of scheduled basis. This therapy demonstrated a 
significant reduction in emergency room visits and 
hospitalizations in a clinical trial.19
Dofetilide (Tikosyn):
      Dofetilide is a Vaughan Williams class III antiar-
rythmic agent. The mechanism of action is to create 
a prolonged action potential as a result of delayed 
repolarization by blocking IKr channels. Dofetilide 
may not be an ideal choice for cardioversion to sinus 
rhythm in the postoperative setting as it may take 
2-3 days to cardiovert and would therefore require 
anticoagulation therapy for stroke prevention. Main-
tenance dosing for dofetilide depends on renal func-
tion as follows: 0.5 mg orally every 12 hours for CrCl 
>60 mL/min, 0.25 mg orally every 12 hours for CrCl 
40-60 mL/min, and 0.125 mg for CrCl 20-40 mL/min. 
Dofetilide is contraindicated in patients with CrCl <20 
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mL/min and for QTc interval >470 msec in men or 
>480 msec in women.20 Other side effects include QT 
prolongation and torsades de pointes (TdP), especial-
ly in patients with heart failure. Dofetilide carries a 
unique treatment initiation limitation as it must be 
started in the inpatient setting to complete 2 hours of 
EKG monitoring after each dose for at least 3 days of 
therapy.
Dronedarone (Multaq):
       Dronedarone is a Vaughan Williams class III an-
tiarrhythmic and has a similar mechanism of action 
to amiodarone which inhibits multiple ion currents 
including sodium, potassium, and calcium currents. 
Additionally, dronedarone is a noncompetitive β-ad-
renergic inhibitor. Dronedarone was associated with 
an increased incidence of mortality compared to 
amiodarone and is therefore contraindicated in pa-
tients with NYHA class III to IV heart failure, unstable 
NYHA class II heart failure, and in patients with per-
manent Afib.21 Furthermore, efficacy of dronedarone 
for maintenance of normal sinus rhythm has only 
been shown in patients with nonsurgical paroxysmal 
Afib and therefore does not qualify as a potential 
treatment for POAF.
Ibutilide (Corvert):
       Ibutilide is a Vaughan Williams class III antiar-
rhythmic agent. It delays repolarization by activation 
of slow, inward sodium current and IKR. Ibutilide is 
only available as an IV dosage form and is therefore 
only used for cardioversion to NSR and not for main-
tenance of NSR. This medication is dosed based on 
weight as follows:  1 mg IV over 10 min for weight 
≥60 kg or 0.01 mg/kg IV administered over 10 min for 
weight <60 kg.22 Side effects that limit the use of ibut-
ilide include QT interval prolongation and TdP. The 
risk for TdP is 2 to 3 fold higher in patients with systol-
ic heart failure. A small prospective randomized pilot 
study compared ibutilide to propafenone and a rate 
control arm. The study found that while every patient 
given ibutilide was successfully cardioverted, 90% of 
these patients also experienced recurrent Afib.23 This 
was statistically significant compared to the lower 
rate of recurrence for both propafenone and the rate 
control arm. Ibutilide may be considered for patients 
with structural heart disease and new-onset POAF 
without hypotension or CHF. Patients must be moni-
tored for at least 6 hours after receiving ibutilide.
Procainamide (Procainamide HCl):
      Procainamide is a Vaughan Williams class 1A 
antiarrhythmic agent. It blocks fast sodium channels 
which increases the effective refractory period of the 
atria, and to a lesser extent the ventricles. It is only 
available as an IV formulation and is therefore only 
indicated for the conversion of Afib to sinus rhythm 
but not for maintenance of sinus rhythm. Addition-
ally, procainamide has only been shown effective for 
conversion in nonoperative Afib as conversion after 
noncardiac thoracic surgery has not been investi-
gated. Dosing of procainamide is more difficult and 
requires close monitoring to assess appropriate 
dose. It is dosed at 20-50 mg/min IV continuous infu-
sion until Afib terminated, hypotension occurs, QRS 
duration prolonged by 50%, or cumulative total dose 
of 15 mg/kg reached. Alternative dosing includes 100 
mg IV every 5 minutes until Afib terminated or previ-
ous mentioned conditions are met.24 Procainamide is 
contraindicated in patients with systolic heart failure 
or pretreatment QTc interval >470 ms in men or >480 
ms in women.
Propafenone (Rythmol):
      Propafenone is a Vaughan Williams class 1C 
antiarrhythmic agent. It reduces upstroke velocity of 
the action potential which is phase 0. A single oral 
dose of 450-600 mg is effective for conversion of 
nonsurgical Afib to sinus rhythm. Propafenone is also 
effective for maintenance of sinus rhythm in patients 
with nonoperative Afib at doses of 150-300 mg (im-
mediate release) orally every 8 hours or 225-425 mg 
(extended release) orally every 12 hours.25 There are 
only oral formulations of propafenone. Side effects 
include dizziness, blurred vision, sinus bradycardia, 
and AV block. Propafenone is contraindicated in 
patients with systolic heart failure or CAD/structural 
heart disease. 
Sotalol (Betapace AF):
      Sotalol has both Vaughan Williams class II and 
class III antiarrhythmic properties since it is a racemic 
mixture. Sotalol is noncardioselective as it blocks β-1 
and -2 receptors leading to decreased heart rate and 
AV nodal conduction. Sotalol also prolongs atrial and 
ventricular action potentials by inhibition of the IKr 
channels that satisfy class III properties. The class III 
effects are only seen at oral doses ≥160mg/day. So-
talol is only formulated as an oral dosage form with a 
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maintenance dose of 40-160 mg orally every 12 hours 
with the interval requiring adjustment based on kid-
ney function. For CrCl 30-59 mL/min, administer dose 
every 24 hours. Administer dose every 36-48 hours in 
patients with CrCl of 10-29 mL/min.26 Side effects of 
sotalol include sinus bradycardia, AV block, QT interval 
prolongation, TdP, heart failure, and bronchospasm. 
Sotalol has been used to reduce the risk of Afib after 
CABG surgery but is not used for conversion of Afib to 
sinus rhythm. Sotalol is contraindicated in patients with 
pretreatment QTc interval >470 ms in men or >480 ms 
in women.
Quinidine (Quinidine gluconate - IV):
       Quinidine is a Vaughan Williams Class 1A antiar-
rhythmic agent. It inhibits both sodium and potassium 
channels. Quinidine can induce QT interval prolon-
gation that leads to TdP and may increase mortality. 
Therefore, quinidine has fallen out of favor for use in 
management of Afib as there are safer and more effica-
cious agents available.
Management of Patients with Preexisting Afib
       Elderly patients, who commonly have multiple 
comorbidities due to their advanced age, are a large 
portion of patients requiring cardiothoracic surgery. 
Oftentimes this patient population will present with 
preexisting Afib preoperatively. The 2014 AATS POAF 
guidelines recommend that cardiology consultations 
be obtained for these patients, and that they should be 
treated according to the existing guidelines for non-
surgical Afib, namely the recently released 2014 AHA/
ACC/HRS guidelines for Afib management.15
       AATS recommends that for patients with pre-
existing Afib, decisions regarding interruption of 
anticoagulation for surgery be made based on the 
patient’s stroke risk versus bleed risk.1 This is done 
with the guidance of the CHA2DS2-VASc score (Figure 
1). In patients with a high risk for stroke (equating to a 
CHA2DS2-VASc score of ≥2), history of a prior stroke, 
or mechanical heart valve, perioperative bridging with 
a parenteral anticoagulant (i.e. enoxaparin) is reason-
able. For patients with a lower risk, short-term with-
drawal without bridging may be appropriate. 
Conclusion
      Postoperative atrial fibrillation is a major complica-
tion of thoracic surgery that, with evidence-based prac-
tice, is often preventable. This complication has several 
implications, the most worrisome being thromboem-
boli formation resulting in stroke. The guidelines 
presented here have provided the most up-to-date 
recommendations on prophylaxis for POAF, treat-
ments strategies, and anticoagulation in patients 
presenting with chronic Afib. It is important that 
pharmacists understand the current treatment 
guidelines for critical care patients such as those 
undergoing cardiothoracic surgery. Ensuring the 
proper pharmacological therapy in these patients 
will help establish better treatment outcomes, de-
crease hospital length of stay, and save money and 
resources. 
Table 1. Modifiable and nonmodifiable risk factors for  
postoperative atrial fibrillation.1 
Modifiable Nonmodifiable 
Hypertension Increasing age 
Myocardial Infarction African American (protective) 
Valvular Heart Disease Family History  
Heart Failure  Genetic Variance 
Obesity Male Sex 
Obstructive Sleep Apnea History of Arrhythmias 
Smoking  
Exercise 
 
Alcohol use 
 
Hyperthyroidism 
 
Increased Pulse Pressure 
 
Mitral Regurgitation 
Left Ventricular Hypertrophy 
 
  
Figure 1. CHA2DS2-VASc scoring system for the prediction of stroke risk in patients with atrial 
fibrillation. A maximum score of 9 is possible. Scores of ≥2 are considered high risk. Adapted from the 
2014 AATS POAF guidelines.1 
LV=left ventricular, BP=blood pressure, HTN=hypertension, TIA=transient ischemic attack, MI=myocardial infarction, PVD=peripheral vascular 
disease 
  Condition Points 
C Congestive heart failure (or LV dysfunction) 1 
H Hypertension BP>140/90 (or treated HTN)  1 
A2 Age ≥75 years 2 
D Diabetes Mellitus 1 
S2 Prior stroke or TIA or Thromboembolism 2 
V Vascular disease (MI, PVD, Aortic plaque) 1 
A Age 65-74 years 1 
Sc Sex Category (female) 1 
 
Figure 2. Vaughan Williams classification of agents. 27 
 
Vaughn-williams Classification 
Class I Sodium-channel-blocking drugs: 
Class IA - Moderately slow conduction, moderately prolonged action potential duration: 
Quinidine 
Procainamide 
Disopyramide 
Class IB - Minimally slow conduction, shortened action potential duration: 
Tocainide 
Lidocaine 
Mexiletine 
Phenytoin 
Class IC - Markedly slow conduction, minimally prolonged action potential duration: 
Flecainide 
Encainide 
Propafenone 
Moricizine 
 
Class II Beta-blocking drugs 
 
Class III Potassium-channel-blocking drugs - prolonged action potential duration: 
Amiodarone 
Bretylium 
Sotalol 
Ibutilide 
 
Class IV Calcium-channel-blocking drugs 
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Table 2. Rate control agents and their clinical pearls.1 
 
HR= heart rate, BP= blood pressure, EKG=electrocardiogram, AV=atrioventricular, HF=heart failure, K+=potassium, Mg2+=magnesium, 
N/V=nausea/vomiting, βB=beta-blocker, CCB=calcium channel blocker,  
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Esmolol
(Brevibloc)
No HR, BP, telemetry/EKG Hypotension, bradycardia, AV 
block, fatigue, dizziness
Titrate dose to goal HR
Metoprolol
(Lopressor)
No HR, BP, telemetry/EKG Hypotension, bradycardia, AV 
block, fatigue, dizziness
Oral dosage form available for 
long-term maintenance 
Diltiazem
(Cardizem)
No HR, BP, telemetry/EKG Hypotension, bradycardia, AV 
block, worsening of HF, peripheral 
edema, constipation
Titrate dose to goal HR
Digoxin
(Lanoxin)
Yes K+, Mg2+, serum drug 
level, HR, 
telemetry/EKG
N/V, anorexia, confusion, visual 
disturbances, AV block, ventricular
arrhythmias 
Therapeutic serum concentration: 
0.8-2ng/mL, does not appreciably 
effect BP, synergistic with βB/CCB
ACPE UAN# 0100-0000-15-044-H03-P; 
0100-0000-15-044-H03-T
To receive CPE credit you must complete the quiz and 
evaluations on page 41 & 42
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            Comparing the 2013 ACC/AHA & 2014 NLA Dyslipidemia Guidelines and their Impact on 
Clinical Decision Making       ACPE UAN# 0100-0000-15-043-H04-P; 0100-0000-15-043-H04-T
1. The ACC/AHA recommends utilizing 
which risk assessment calculator?
a. Pooled Cohort equations
b. Framingham risk calculator
c. Framingham long-term risk calculator
d. A & B
e. All of the above
2. AD is a 56 year-old male who presents to 
the lipid clinic for evaluation of his choles-
terol. He has never had a fasting lipid panel 
performed and was referred to the clinic 
by his primary care physician. According 
to the NLA, which component of a fasting 
lipid panel is considered a primary target 
for modification?
a. LDL-C
b. Non-HDL-C
c. apoB
d. HDL-C
3. AD’s fasting lipid panel results reveal an 
LDL-C of 196mg/dL. How would you classi-
fy AD’s risk based on his LDL-C level alone, 
based on the NLA recommendations?
a. Low risk
b. Moderate risk
c. High risk
d. Very high risk
4. Based on AD’s above risk category, what 
pharmacotherapy would you recommend 
initiating, per the NLA recommendations?
a. Atorvastatin 40mg daily
b. Pravastatin 20mg daily
c. Lovastatin 40mg daily
d. Simvastatin 20mg daily
5. Which of the following is/are considered 
clinical ASCVD?
a. Myocardial infarction
b. Stroke/TIA
c. Peripheral artery disease
d.  All of the above
6. Which of the following medications 
should be selected for a patient with Type 
II diabetes and a non-HDL-C of 128 mg/dL 
according to the NLA recommendations?
a. Fenofibrate 145 mg daily
b. Niacin 100 mg TID
c. Atorvastatin 20 mg daily Ezetimibe 10 mg 
daily
7. MJ is a 44 year-old male who has been 
referred to your facility’s lipid clinic for 
the management of his dyslipidemia. He 
has a LDL-C of 164 mg/dL and a HDL-C of 
58 mg/dL. The patient reports that his 
father passed away at 54 years of age from 
a heart attack, but his mother is healthy 
without any significant health concerns. He 
has hypertension with a blood pressure 
reading of 158/92 mm Hg today at his 
follow-up visit. How many risk factors for 
ASCVD does this patient have?
a. 0
b. 1
c. 2
d. 3
8. Which of the following statements is 
true about non-HDL-C and Apo B?
a. Both are considered a secondary target 
in the treatment of atherogenic choles-
terol in the NLA recommendations for the 
treatment of dyslipidemia.
b. Neither of the two requires fasting 
prior to a lipid panel for accurate assess-
ment.
c. Apo B has shown superiority to non-
HDL-C in randomized controlled trials in 
predicting ASCVD risk.
d. The treatment goals for non-HDL-C and 
Apo B are the same despite which risk 
category the patient falls under.
9. You are a pharmacist on rounds with 
a physician in the hospital setting. Your 
primary responsibility this morning as 
the pharmacist is to provide recommen-
dations for the renal dose adjustment 
of medications in a patient with stage 4 
chronic kidney disease. The patient is 65 
years old, smokes one pack of cigarettes 
per day and has stage II hypertension. 
The results of the lipid panel confirm 
that the patient has dyslipidemia with a 
non-HDL-C of 155 mg/dL and an LDL-C of 
110 mg/dL. The physician wants to start 
a statin in this patient but is unfamiliar 
with the new NLA recommendations 
and what risk category the patient falls 
under. He also wants to know what the 
patient’s goal non-HDL-C is based on 
his risk category. What is the correct 
response to the physician?
a. The patient is at moderate risk with a 
non-HDL-C goal of <130 mg/dL
b. The patient is at very high risk with a 
non-HDL-C goal of <100mg/dL
c. The patient is at high risk with a non-
HDL-C goal of <130 mg/dL
d. You cannot give an appropriate answer 
at this time because quantitative risk 
scoring is required to further assess the 
patient’s risk category and cholesterol 
goals.
10. Comparing the 2013 ACC/AHA guide-
lines and the 2014 NLA recommenda-
tions what is/are the major differences?
CONTINUING EDUCATION QUIZ QUESTIONS
I.
a. The NLA recommendations use of 
non-HDL-C, LDL-C, and Apo-B target goals 
in the treatment of dyslipidemia where 
the ACC/AHA guidelines do not utilize 
treatment goals.
b. The NLA recommendation of using 
Apo-B as the primary lipid measure to tar-
get treatment goals as opposed to LDL-C 
by the ACC/AHA guidelines.
c. The NLA recommendation of using 
fibrates as an initial treatment option in 
patients that fall into the moderate risk 
ASCVD group compared to the ACC/AHA 
guidelines that recommend statin use 
first line.
d. A and C
11. Which of the following statements of 
the NLA recommendations is true:
a. Patients that fall into the very high risk 
ASCVD category should have an initial TLC 
trial prior to pharmacotherapy initiation.
b. The NLA does not recommend the use 
of quantitative risk scoring in patients 
being evaluated for dyslipidemia that fall 
into the high and very high risk categories 
as it typically underestimates their risk for 
an ASCVD event.  
c. TLC changes such as initiating or in-
creasing exercise regimens to 30 minutes/
day, adding 5-10g of viscous fiber to diet, 
and 5-10% weight loss for all patients 
should be started at initial evaluation for 
patients who have dyslipidemia.
d. The NLA recommends fibrates, nicotin-
ic acids, and statins to be considered first 
line therapy in treating patients newly 
diagnosed with dyslipidemia. 
Use the following patient case to #12-14:
RD is a 63 years old male (70in, 249lbs) 
with a history of COPD, DM, 1 PPD smok-
er, total hip replacement and HTN. He 
is returning after 3 months to the clinic 
where you the clinical pharmacist have 
authority to adjust pharmacotherapy in 
patients with dyslipidemia. RD is   com-
plaining of muscle pain and weakness at 
his follow up visit after he was started on 
atorvastatin 40mg. 
Creatinine Kinase: within normal limits 
LFTs: within normal limits Non-HDL cho-
lesterol(baseline/current): 232/156 mg/
dL; HDL-C(baseline/current): 40/45 mg/dL
TG (baseline/current): 430/389mg/dL; 
Current BP is 132/78; Current meds: Lis-
inopril 40mg PO daily, amlodipine 10mg 
PO daily, Metformin 1000mg PO BID, 
Glipizide 5mg PO BID, Symbicort 160/4.5 
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 1. Which of the following is a major complica-
tion associated with POAF?
a. Vision changes
b. Insufficient blood flow leading to poor perfu-
sion to the body
c. Moderate to severe skin reactions
d. Increased risk of bleed due to inability to 
coagulate
2. Which  is/are symptoms of POAF?
a. Excessive weight gain
b. Increased thirst (polydipsia) and increased 
urination (polyuria)
c. Brittle nails
d. Hypotension and fatigue
3. Which of the following statements is TRUE 
regarding β-blockers?
a. β-blockers are Vaughan Williams class IV 
agents
b. Tachycardia and hypertension are common 
side effects of β-blocker therapy
c. IV dosing of metoprolol tartrate (Lopressor) is 
12.5-25 mg IV bolus over 2 min for a maximum 
of three doses
d. Patients with systolic heart failure and/or 
CAD have a compelling indication for β-blocker 
therapy
4. JW is a 72 yo M who is currently taking me-
toprolol tartrate 50 mg BID. He has no history 
of AF but is undergoing a pulmonary segmen-
tectomy. Which of the following statements is 
most accurate?
a. JW should be started on digoxin 0.125 mg for 
AF prophylaxis
b. Metoprolol should be discontinued prior to 
surgery
c. Continue metoprolol since JW was taking 
prior to surgery 
d. Beta-blocker therapy is contraindicated in 
thoracic surgeries
A Pharmacist’s Role in the Prevention and Management of Perioperative Atrial Fibrillation and Flutter   
ACPE UAN# 0100-0000-15-044-H03-P; 0100-0000-15-044-H03-T
II.
2 puffs BID
12. Based on RDs current status the most appropriate 
change to therapy would be to:
a. Discontinue atorvastatin 40mg as it causing myopathies.
b. Decrease his dose of atorvastatin to 20mg and add long 
chain omega-3 fatty acids to decrease his TG.
c. Change atorvastatin to rosuvastatin 20mg. 
d. Stop all statin use as RD is intolerant to statins and start 
fenofibrate 135 mg.
13. What therapeutic lifestyle changes (TLC) should be rec-
ommended to RD to help him reach his non-HDL-C goal:
a. Counsel RD on smoking cessation and refer him to the 
Arizona Smokers Helpline (ASH-Line)
b. Suggest moderate exercise for 30 minutes per day, 7 days 
week, as possible
c. Recommend following DASH diet
d. All of the above are appropriate lifestyle changes
14. RD returns to the clinic after another 3 months after follow-
ing the recommendations made at his previous visit. His current 
non-HDL-C is 130mg/dL. Which of the following is false?
a. RDs adherence and tolerability to his pharmacotherapy and TLC 
need to be assessed.
b. RD has reached his non-HDL-C goal and can discontinue therapy 
and follow up in 12 months.
c. RD should be evaluated and encouraged for smoking cessation.
d. TLC changes should be discontinued as he has reached his goal 
non-HDL-C.
e. B and D
5. Which of the following is a unique side 
effect of diltiazem?
a. Constipation
b. Diarrhea
c. Visual disturbances
d. Alopecia
6. All of the following are monitoring 
parameters for digoxin EXCEPT:
a. Serum drug concentration (goal: 0.8 - 
2.0 ng/mL for Afib)
b. Electrolytes
c. Liver function
d. Kidney function
7. Which of the following statements 
regarding amiodarone is FALSE?
a. Amiodarone can be used for cardio-
version from AFib to sinus rhythm or for 
maintenance of sinus rhythm.
b. Amiodarone is available in IV and oral 
formulations.
c. Amiodarone does not cause bradycar-
dia or hypotension.
d. Amiodarone should be used cautiously 
in patients on oral anticoagulation as it 
inhibits the metabolism of warfarin and 
inhibits the elimination of the new oral 
anticoagulants.
8. Which rhythm control agent must 
be started in an inpatient setting for a 
minimum of 3 days?
a. Propafenone
b. Amiodarone
c. Dofetilide
d. Verapamil
LT is a 68 y/o female s/p thoracic surgery. 
Her BP is 132/88 with a HR of 78. She 
is hemodynamically stable yet having 
symptoms of AFib including shortness 
of breath, fatigue, and confusion. Rate 
control agents are not sufficiently treating 
POAF in LT. Use this case for #9 – 10.
9. LT is a candidate for rhythm control for 
POAF.
a. True
b. False
10. Which of the following medications 
cannot be used to cardiovert LT?
a. Amiodarone
b. Sotalol
c. Ibutilide
d. All of these can be used to pharmacologi-
cally cardiovert.
11. Which of the following is NOT a rec-
ommendation provided by the 2014 AATS 
guidelines for preventing POAF?
a. Supplemental intravenous magnesium 
should be considered for patients in which 
serum magnesium levels are low
b. Patients taking beta-blockers prior to 
surgery to continue to take them in the 
postoperative period
c. Initiate sotalol preoperatively as prophy-
laxis for POAF
d. Digoxin should not be used for prevent-
ing POAF
GL is a 72 y/o male who will be undergoing 
a lung transplantation next week. His PMH 
includes chronic Afib, DM, HTN and gout. 
12. GL’s CHA2DS2-VASc score is:
a. 1
b. 2
c. 3
d. 4
13. Perioperative anticoagulation bridging 
should be considered for GL:
a. True
b. False
